AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23118533 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional physiotherapy plus inspiratory muscle training (IMT) with a Threshold IMT(®) device
Number of subjects: 28
Study 23118533 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy
Number of subjects: 28
Study 20975107 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextrose meal (2.25 g/kg)
Number of subjects: 10
Study 20975107 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin meal (2.25 g/kg)
Number of subjects: 10
Study 17935636 — intervention group
Group type: EXPERIMENTAL
Intervention: Orientation statement letter delivered 24-48 h before the first appointment
Number of subjects: 764
Study 17935636 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 764
Study 15790438 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel + Carboplatin (PC)
Number of subjects: 90
Study 15790438 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel + Carboplatin + Amifostine (PC + A)
Number of subjects: 90
Study 15790438 — intervention group
Group type: EXPERIMENTAL
Intervention: Amifostine
Number of subjects: 90
Study 14634942 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mL bupivacaine 0.5%
Number of subjects: 29
Study 14634942 — intervention group
Group type: COMPARATOR
Intervention: 4 mL saline 0.9%
Number of subjects: 29
Study 10390665 — intervention group
Group type: EXPERIMENTAL
Intervention: granisetron 40 mg kg‐1
Number of subjects: 90
Study 10390665 — intervention group
Group type: COMPARATOR
Intervention: perphenazine 70 mg kg‐1
Number of subjects: 90
Study 8877766 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenine arabinoside 5'‐monophosphate (ARA‐AMP), 5 mg/kg/day during 7 weeks
Number of subjects: 20
Study 8877766 — intervention group
Group type: COMPARATOR
Intervention: Lymphoblastoid interferon (ly‐IFN), 5,000,000 units, three times per week, during 4 months
Number of subjects: 20
Study 8877766 — intervention group
Group type: COMPARATOR
Intervention: Lymphoblastoid interferon (ly‐IFN)
Number of subjects: 20
Study 8877766 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenine arabinoside 5'‐monophosphate (ARA‐AMP)
Number of subjects: 20
Study 1611974 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anaesthesia nerve blocks in the pterygomandibular space
Number of subjects: 506
Study 1611974 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial nerve resection and microsurgical reconstruction
Number of subjects: 506
Study 6357595 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg epirizole for 14 days
Number of subjects: 10
Study 6357595 — intervention group
Group type: COMPARATOR
Intervention: 3000 mg ASA
Number of subjects: 10
Study 6357595 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg epirizole
Number of subjects: 10
Study 2859465 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium bis acetyl homotaurine (Ca AOTA, 25 mg/kg/day)
Number of subjects: 85
Study 2859465 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 31088531 — intervention group
Group type: EXPERIMENTAL
Intervention: Video intervention therapy (VIT) consisting of four modules with one video-recorded play session and one VIT session per week.
Number of subjects: 0
Study 31088531 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual plus weekly play sessions (Control group).
Number of subjects: 0
Study 29976251 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual or combined water, sanitation, handwashing, and nutrition interventions
Number of subjects: 5551
Study 29976251 — intervention group
Group type: EXPERIMENTAL
Intervention: Handwashing interventions
Number of subjects: 5551
Study 29976251 — intervention group
Group type: EXPERIMENTAL
Intervention: Water intervention arms
Number of subjects: 5551
Study 29976251 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition arms
Number of subjects: 5551
Study 29976251 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 5551
Study 26859512 — intervention group
Group type: EXPERIMENTAL
Intervention: NCPAP via binasal prongs (NP)
Number of subjects: 149
Study 26859512 — intervention group
Group type: COMPARATOR
Intervention: NCPAP via nasal mask (NM)
Number of subjects: 149
Study 24617745 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-adolescent family functioning discrepancies
Number of subjects: 746
Study 22482940 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (3 mg/m² on days 1, 4, and 7 during induction and day 1 of each of the two consolidation chemotherapy courses)
Number of subjects: 280
Study 22482940 — intervention group
Group type: COMPARATOR
Intervention: Control (standard treatment)
Number of subjects: 280
Study 22482940 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin
Number of subjects: 280
Study 22482940 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 280
Study 20630463 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stents (ZES)
Number of subjects: 44
Study 20630463 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 44
Study 18929703 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive lovastatin treatment (LDL cholesterol target <85 mg/dl)
Number of subjects: 1116
Study 18929703 — intervention group
Group type: COMPARATOR
Intervention: Moderate lovastatin treatment (LDL cholesterol target <140 mg/dl)
Number of subjects: 1116
Study 16029263 — intervention group
Group type: EXPERIMENTAL
Intervention: Axial length measurement
Number of subjects: 663
Study 16029263 — intervention group
Group type: EXPERIMENTAL
Intervention: Refraction measurement
Number of subjects: 663
Study 16029263 — intervention group
Group type: COMPARATOR
Intervention: Comparison of different ARM stages
Number of subjects: 663
Study 16029263 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex differences in axial length and refraction
Number of subjects: 663
Study 14644225 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouse EVES with HMD viewing
Number of subjects: 70
Study 14644225 — intervention group
Group type: COMPARATOR
Intervention: Optical magnifier
Number of subjects: 70
Study 14644225 — intervention group
Group type: EXPERIMENTAL
Intervention: All EVES
Number of subjects: 70
Study 10873108 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS-1 with OKT3 activation for 72 hours
Number of subjects: 0
Study 10873108 — intervention group
Group type: EXPERIMENTAL
Intervention: OKT3 activation
Number of subjects: 0
Study 10873108 — intervention group
Group type: COMPARATOR
Intervention: PBS, interleukin-2, OKT3, or interleukin-2/OKT3 for T-cell activation
Number of subjects: 0
Study 8641743 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendrofluazide 5 mg once daily
Number of subjects: 18
Study 8641743 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 100 mg once daily
Number of subjects: 18
Study 8641743 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 1298186 — intervention group
Group type: EXPERIMENTAL
Intervention: SIN-1 (1 mg)
Number of subjects: 12
Study 1298186 — intervention group
Group type: COMPARATOR
Intervention: Isosorbide dinitrate (5 mg)
Number of subjects: 12
Study 6237916 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil 15 mg
Number of subjects: 10
Study 6237916 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil 30 mg
Number of subjects: 10
Study 6237916 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil 60 mg
Number of subjects: 10
Study 6237916 — intervention group
Group type: COMPARATOR
Intervention: Isosorbide dinitrate (ISDN) 5 mg
Number of subjects: 10
Study 6237916 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30613065 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab plus glucocorticoid (GC)
Number of subjects: 0
Study 30613065 — intervention group
Group type: EXPERIMENTAL
Intervention: Avacopan (CCX168)
Number of subjects: 0
Study 30613065 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 0
Study 30375699 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine plus lamotrigine
Number of subjects: 201
Study 30375699 — intervention group
Group type: COMPARATOR
Intervention: Quetiapine monotherapy
Number of subjects: 201
Study 30375699 — intervention group
Group type: COMPARATOR
Intervention: Folic acid
Number of subjects: 201
Study 30375699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study 27009317 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical behavior therapy skills training
Number of subjects: 0
Study 27009317 — intervention group
Group type: COMPARATOR
Intervention: Relaxation training (supportive discussion and instruction)
Number of subjects: 0
Study 25153504 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic balloon dilation for CD strictures
Number of subjects: 90
Study 25153504 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic balloon dilation for non-CD strictures
Number of subjects: 90
Study 25153504 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic balloon dilation for both groups
Number of subjects: 90
Study 22302565 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical control measures
Number of subjects: 160
Study 22302565 — intervention group
Group type: EXPERIMENTAL
Intervention: Both chemical (tannic acid) and physical interventions
Number of subjects: 160
Study 22302565 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemical intervention (tannic acid)
Number of subjects: 160
Study 22302565 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 160
Study 19793859 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate energy supplementation (15,058 +/- 6211 kcal over 21 days, >6 kcal x kg(‐1) x d(‐1))
Number of subjects: 41
Study 19793859 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 41
Study 17150247 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin and cisplatin treatment in Stage III/IV patients with BMI ≥ 40
Number of subjects: 949
Study 17150247 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin and cisplatin treatment in patients with higher BMI
Number of subjects: 949
Study 17150247 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin and cisplatin treatment
Number of subjects: 949
Study 16398437 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint electro-superconducting therapy with Chinese herbal drugs contained pad
Number of subjects: 60
Study 16398437 — intervention group
Group type: COMPARATOR
Intervention: Placebo pad
Number of subjects: 60
Study 12480356 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg single-dose mifepristone
Number of subjects: 4136
Study 12480356 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg single-dose levonorgestrel
Number of subjects: 4136
Study 12480356 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of 0.75 mg levonorgestrel given 12 hours apart
Number of subjects: 4136
Study 12480356 — intervention group
Group type: COMPARATOR
Intervention: Levonorgestrel (the two regimens combined)
Number of subjects: 4136
Study 10375949 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor efficiency examination in patients with CSPS
Number of subjects: 71
Study 10375949 — intervention group
Group type: EXPERIMENTAL
Intervention: Range of active movements
Number of subjects: 71
Study 10375949 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength of muscle groups
Number of subjects: 71
Study 10375949 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor efficiency parameters
Number of subjects: 71
Study 10375949 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor efficiency examinations
Number of subjects: 71
Study 8970267 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week training intervention
Number of subjects: 109
Study 2003792 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.01% dexamethasone sodium phosphate drops
Number of subjects: 12
Study 2003792 — intervention group
Group type: COMPARATOR
Intervention: Artificial tears alone (Control)
Number of subjects: 12
Study 6722395 — intervention group
Group type: EXPERIMENTAL
Intervention: Apomorphine (0.75 mg s.c.)
Number of subjects: 0
Study 6722395 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30733966 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 822
Study 30733966 — intervention group
Group type: COMPARATOR
Intervention: Sham-acupuncture (SA)
Number of subjects: 822
Study 30228027 — intervention group
Group type: COMPARATOR
Intervention: Regorafenib
Number of subjects: 0
Study 30228027 — intervention group
Group type: COMPARATOR
Intervention: TAS-102
Number of subjects: 0
Study 30228027 — intervention group
Group type: EXPERIMENTAL
Intervention: Best Supportive Care (BSC)
Number of subjects: 0
Study 27067836 — intervention group
Group type: EXPERIMENTAL
Intervention: Andrew's manoeuvre (four-hands CC) during DA-CPR
Number of subjects: 68
Study 27067836 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard DA-CPR without Andrew's manoeuvre)
Number of subjects: 68
Study 27067836 — intervention group
Group type: EXPERIMENTAL
Intervention: Female intervention group (with Andrew's manoeuvre)
Number of subjects: 68
Study 27067836 — intervention group
Group type: COMPARATOR
Intervention: Female control group (without Andrew's manoeuvre)
Number of subjects: 68
Study 25902891 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone, opioid, and saline admixture (NOSA) containing 12 μg naloxone per 1 mg morphine per 1 mL normal saline.
Number of subjects: 92
Study 25902891 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving morphine only.
Number of subjects: 92
Study 25902891 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone, opioid, and saline admixture (NOSA)
Number of subjects: 92
Study 23043123 — intervention group
Group type: EXPERIMENTAL
Intervention: Sparklines
Number of subjects: 20
Study 23043123 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative multigraphs
Number of subjects: 20
Study 23043123 — intervention group
Group type: EXPERIMENTAL
Intervention: Absolute multigraphs
Number of subjects: 20
Study 23043123 — intervention group
Group type: EXPERIMENTAL
Intervention: Tables
Number of subjects: 20
Study 21079814 — intervention group
Group type: EXPERIMENTAL
Intervention: Striatum activation during successful stopping
Number of subjects: 24
Study 21079814 — intervention group
Group type: EXPERIMENTAL
Intervention: Striatum activation proportional to left M1 deactivation
Number of subjects: 24
Study 21079814 — intervention group
Group type: EXPERIMENTAL
Intervention: Striatum activation linked to stop-signal probability
Number of subjects: 24
Study 21079814 — intervention group
Group type: EXPERIMENTAL
Intervention: Striatum activation linked to SMC and rIFC
Number of subjects: 24
Study 21079814 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial-to-trial variations in response time
Number of subjects: 24
Study 18066530 — intervention group
Group type: EXPERIMENTAL
Intervention: Open repair (group A)
Number of subjects: 40
Study 18066530 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous repair with Tenolig (group B)
Number of subjects: 40
Study 18066530 — intervention group
Group type: COMPARATOR
Intervention: Both open and percutaneous techniques
Number of subjects: 40
Study 16611287 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate 1 microg/kg x min
Number of subjects: 9
Study 16611287 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 9
Study 14550427 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin (500 mg/day) for 6 weeks
Number of subjects: 80
Study 14550427 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 80
Study 10781643 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E 200 mg/day
Number of subjects: 37
Study 10781643 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E 400 mg/day
Number of subjects: 37
Study 9165857 — intervention group
Group type: EXPERIMENTAL
Intervention: Home support from a trained oncology nurse during treatment
Number of subjects: 0
Study 9165857 — intervention group
Group type: COMPARATOR
Intervention: Visits after treatment
Number of subjects: 0
Study 1492458 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 IE EPO/kg 2 x/week i.v. over 3 weeks (group C)
Number of subjects: 82
Study 1492458 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 IE EPO 2 x/week i.v. over 3 weeks (group B)
Number of subjects: 82
Study 1492458 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group A)
Number of subjects: 82
Study 3927958 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine 30 mg thrice daily
Number of subjects: 66
Study 3927958 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine 40 mg thrice daily
Number of subjects: 66
Study 3927958 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 66
Study 3927958 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 31945816 — intervention group
Group type: EXPERIMENTAL
Intervention: GCWB104 (300 mg containing 125 mg of Flos Lonicera extract, twice daily)
Number of subjects: 92
Study 31945816 — intervention group
Group type: COMPARATOR
Intervention: Placebo (300 mg, twice daily)
Number of subjects: 92
Study 30293770 — intervention group
Group type: EXPERIMENTAL
Intervention: LY3298176 (1 mg)
Number of subjects: 316
Study 30293770 — intervention group
Group type: EXPERIMENTAL
Intervention: LY3298176 (5 mg)
Number of subjects: 316
Study 30293770 — intervention group
Group type: EXPERIMENTAL
Intervention: LY3298176 (10 mg)
Number of subjects: 316
Study 30293770 — intervention group
Group type: EXPERIMENTAL
Intervention: LY3298176 (15 mg)
Number of subjects: 316
Study 30293770 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 316
Study 30293770 — intervention group
Group type: COMPARATOR
Intervention: Dulaglutide (1.5 mg)
Number of subjects: 316
Study 30293770 — intervention group
Group type: COMPARATOR
Intervention: Dulaglutide
Number of subjects: 316
Study 30293770 — intervention group
Group type: EXPERIMENTAL
Intervention: LY3298176
Number of subjects: 316
Study 26990722 — intervention group
Group type: EXPERIMENTAL
Intervention: Explosive-type strength training of the plantar flexors (2 days per week for 4 weeks, 3 sets of 10 repetitions lasting less than 1 second)
Number of subjects: 56
Study 26990722 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 56
Study 24998258 — intervention group
Group type: EXPERIMENTAL
Intervention: Early renal replacement therapy
Number of subjects: 864
Study 24998258 — intervention group
Group type: COMPARATOR
Intervention: Delayed renal replacement therapy
Number of subjects: 864
Study 22051059 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 100 mg once daily
Number of subjects: 17
Study 22051059 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 21088400 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxin (intravenous doses)
Number of subjects: 234
Study 21088400 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 234
Study 19029516 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous IGF-1 (0.05 mg/kg body weight, twice daily)
Number of subjects: 330
Study 19029516 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 330
Study 16234008 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy (FSG) performance by examiners
Number of subjects: 50000
Study 12805341 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 50
Study 10827388 — intervention group
Group type: EXPERIMENTAL
Intervention: Local delivery of 5000 U heparin infused into the arterial wall
Number of subjects: 179
Study 10827388 — intervention group
Group type: COMPARATOR
Intervention: Intraluminal delivery of 5000 U heparin administered to the coronary artery lumen
Number of subjects: 179
Study 8846277 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Controlled Analgesia (PCA) using morphine
Number of subjects: 30
Study 8846277 — intervention group
Group type: COMPARATOR
Intervention: Continuous morphine infusion
Number of subjects: 30
Study 8198941 — intervention group
Group type: COMPARATOR
Intervention: 1 mg kg‐1 intravenous lignocaine
Number of subjects: 27
Study 8198941 — intervention group
Group type: COMPARATOR
Intervention: 1 mg kg‐1 intravenous lignocaine (fed)
Number of subjects: 27
Study 8198941 — intervention group
Group type: COMPARATOR
Intervention: 1 mg kg‐1 intravenous lignocaine (fasted)
Number of subjects: 27
Study 3332678 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical benzyl alcohol (BA)
Number of subjects: 0
Study 3332678 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3332678 — intervention group
Group type: COMPARATOR
Intervention: Catalin
Number of subjects: 0
Study 29030160 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile application (PBAC app)
Number of subjects: 25
Study 29030160 — intervention group
Group type: COMPARATOR
Intervention: Paper diary (PBAC)
Number of subjects: 25
Study 27321610 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory-encoding strategy ("If I see Cue X, then I will perform Intention Y")
Number of subjects: 72
Study 27321610 — intervention group
Group type: COMPARATOR
Intervention: Standard encoding condition
Number of subjects: 72
Study 26358690 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban 10 mg oral dose
Number of subjects: 0
Study 26358690 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 0
Study 26358690 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal function assessment methods (iohexol clearance, Cockcroft-Gault, MDRD)
Number of subjects: 0
Study 23587538 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized uterosacral ligament suspension colpopexy (USLSC)
Number of subjects: 0
Study 23587538 — intervention group
Group type: COMPARATOR
Intervention: Control group (no USLSC)
Number of subjects: 0
Study 20354859 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac phonophoresis
Number of subjects: 60
Study 20354859 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound therapy
Number of subjects: 60
Study 20354859 — intervention group
Group type: COMPARATOR
Intervention: Placebo ultrasound therapy
Number of subjects: 60
Study 19494795 — intervention group
Group type: EXPERIMENTAL
Intervention: NGX-4010 capsaicin patch (640 microg/cm2) applied for 60 minutes
Number of subjects: 173